All News

2018

November

Media Release / Nov 02, 2018

Sandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needs

Read More

October

Media Release / Oct 31, 2018

Sandoz receives US FDA approval for biosimilar Hyrimoz™ (adalimumab-adaz)

Read More
Media Release / Oct 18, 2018

Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth

Read More
Media Release / Oct 11, 2018

Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access

Read More
Media Release / Oct 04, 2018

Sandoz Healthcare Access Challenge (HACk) returns, seeking digital solutions to local healthcare access challenges

Read More

September

Media Release / Sep 21, 2018

Sandoz receives positive CHMP opinion for proposed biosimilar pegfilgrastim

Read More
Media Release / Sep 06, 2018

Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo

Read More

July

Media Release / Jul 27, 2018

Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)

Read More
Media Release / Jul 18, 2018

Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company

Read More

June

Media Release / Jun 15, 2018

Sandoz presents new long-term and switching data for biosimilars Zessly® (infliximab) and Erelzi® (etanercept) in rheumatoid arthritis

Read More